Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
ACE Inhibitors Market Forecast: Value Set To Climb From $7.84 Billion To $10.1 Billion
The ace inhibitors market has experienced substantial growth in recent years. It is projected to expand from $7.41 billion in 2025 to $7.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be linked to the rising prevalence of hypertension, heightened awareness regarding cardiovascular diseases, the introduction of first-generation ace inhibitors, an increasing geriatric population, and advancements in drug formulation.
The ace inhibitors market is set for robust expansion over the next few years, with its size forecast to reach $10.11 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This growth throughout the projected period is attributed to several factors including the rising demand for personalized medicine, the integration of digital health solutions, the expansion of new markets, the innovation of novel ace inhibitor combinations, and the increase in home healthcare services. Prominent trends anticipated in the forecast period involve personalized hypertension management, the use of telemedicine and remote patient monitoring, advancements in combination therapy, a surge in generic ace inhibitors, and the broadening of home healthcare solutions.
Get A Free Sample Report With In-Depth Market Insights:
ACE Inhibitors Market Growth Drivers: What’s Behind The Acceleration?
The rising occurrence of cardiac conditions is projected to boost the expansion of the ACE inhibitors market in the future. Cardiac disorders are defined as various medical ailments impacting the heart or blood vessels, covering conditions such as coronary artery disease, heart failure, and arrhythmias. ACE inhibitors are vital in managing these conditions by blocking the angiotensin-converting enzyme, which in turn lessens vasoconstriction, sodium retention, and aldosterone secretion, ultimately enhancing heart function. For example, data from the American Heart Association, a US non-profit, indicated that in January 2024, the age-adjusted death rate due to cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the growing frequency of cardiac disorders is propelling the ACE inhibitors market’s growth.
ACE Inhibitors Market Segments: Where Is Growth Concentrated?
The ace inhibitors market covered in this report is segmented –
1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users
Subsegments:
1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril
2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
3) By Phosphonate-Containing Agents: Fosinopril, Fosinopril Sodium, Fosinopril Calcium
ACE Inhibitors Market Trends: What’s Defining The Industry’s Next Phase?
Leading firms within the ACE inhibitor market are intensifying their efforts to launch generic medications, aiming to secure a competitive advantage. Such drugs possess identical active components, dosing, safety profile, potency, administration method, and efficacy as their brand-name counterparts, yet they are generally offered at a reduced price point after the original patent lapses. For example, in August 2023, Pharmascience Inc., a pharmaceutical company based in Canada, introduced pms-PERINDOPRIL-INDAPAMIDE. This generic drug is designed for the initial management of mild to moderate essential hypertension (high blood pressure) in adult patients. This combined formulation contains two active substances: perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor that assists in blood vessel relaxation, and indapamide, a chlorosulphamoyl diuretic that helps expel surplus fluid and sodium from the body. These components collaboratively reduce blood pressure effectively across a wide spectrum of patients. pms-PERINDOPRIL-INDAPAMIDE is available in several dosage strengths, specifically 2 mg, 4 mg, and 8 mg of perindopril erbumine, combined with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide, respectively.
ACE Inhibitors Market Key Participants And Competitive Landscape
Major companies operating in the ace inhibitors market are Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.
View The Full ACE Inhibitors Market Report:
ACE Inhibitors Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the ACE inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
